Wiley Blackwell

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Kemeny
    Kemeny
  3. Horwitz
    Horwitz
  4. Marghoob
    Marghoob
  5. Kelsen
    Kelsen
  6. Scher
    Scher
  7. Hudis
    Hudis
  8. O'Reilly
    O'Reilly
  9. Tuttle
    Tuttle
  10. Bajorin
    Bajorin

Groups

  1. Department of Medicine (1537)
  2. Solid Tumor Oncology Division (892)
  3. Survivorship Research (499)
  4. Hematologic Malignancies, Division of (432)
  5. Division of Subspecialty Medicine (380)
  6. Center for Hematologic Malignancies (343)
  7. Population Sciences Research Program (289)
  8. Genitourinary Oncology Service (269)
  9. GSK Faculty (263)
  10. Surgery (257)
Search Within
  1. "Department of Medicine"
Formats
  1. Journal Article (982)
  2. Meeting Abstract (382)
  3. Review (52)
  4. Book Section (37)
  5. Research Letter (28)
  6. Editorial (26)
  7. Conference Paper (13)
  8. Guidelines (8)
  9. Correspondence (6)
  10. Miscellaneous (2)
  11. Book Whole (1)
Groups
  1. Department of Medicine (1537)
  2. Solid Tumor Oncology Division (892)
  3. Survivorship Research (499)
  4. Hematologic Malignancies, Division of (432)
  5. Division of Subspecialty Medicine (380)
  6. Center for Hematologic Malignancies (343)

More Groups

People
  1. Robert Motzer (87)
  2. Nancy Kemeny (59)
  3. Steven Horwitz (55)
  4. Ashfaq Marghoob (53)
  5. David Kelsen (49)
  6. Howard Scher (46)

More People

Years
  1. 2025 (48)
  2. 2024 (60)
  3. 2023 (133)
  4. 2022 (54)
  5. 2021 (106)
  6. 2020 (81)

More Years

Publications
  1. Cancer (541)
  2. Hematological Oncology (167)
  3. BJU International (75)
  4. Journal of Surgical Oncology (61)
  5. Asia-Pacific Journal of Clinical Oncology (58)
  6. Cancer Medicine (58)

More Publications

Results (1537)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL): Extended follow‐up and landmark analyses from a pivotal phase II study
    Meeting Abstract

    Dickinson, M.; Carlo‐Stella, C.; Morschhauser, F.; Falchi, L.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez‐Lopez, J.; Bartlett, N.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Bispecific anti‐CD20/19 CAR‐T—zamtocabtagene autoleucel for relapsed/refractory DLBCL—Interim analysis results of DALY‐II‐USA study
    Meeting Abstract

    Ulrickson, M.; Miklos, D. B.; Maziarz, R. T.; Jacobson, C.; Isufi, I.; Ghosh, M.; Perales, M.; Lunning, M.; Hardy, N. M.; Wijatyk, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in covalent BTK‐inhibitor pre‐treated mantle cell lymphoma: Updated results, subgroup analysis from bruin with >3 years follow‐up from start of enrollment
    Meeting Abstract

    Cheah, C. Y.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I.; Alencar, A. J.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Durables responses with anti‐CD19 allogeneic CAR T ALLO‐501/501A in phase 1 trials of relapsed/refractory large B‐cell lymphoma (R/R LBCL)
    Meeting Abstract

    Locke, F. L.; Lekakis, L.; Eradat, H.; Munoz, J.; Tees, M.; de Vos, S.; Nath, R.; Stevens, D.; Malik, S.; Popplewell, L.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in high‐risk follicular lymphoma, regardless of POD24 status
    Meeting Abstract

    Belada, D.; Falchi, L.; Leppä, S.; Vermaat, J. S.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; Nijland, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T‐cell therapy outcome
    Meeting Abstract

    Imber, B. S.; Silverman, E. A.; Leithner, D.; Hubbeling, H.; Shah, G. L.; Fregonese, B.; Sanin, B. W.; Tomas, A. A.; Parascondola, A.; Saldia, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Primary overall survival analysis of the phase 3 randomized ZUMA‐7 study of axicabtagene ciloleucel versus standard of care in relapsed/refractory large B‐cell lymphoma
    Meeting Abstract

    Westin, J. R.; Oluwole, O. O.; Kersten, M. J.; Miklos, D. B.; Perales, M. A; Ghobadi, A.; Rapoport, A. P.; Sureda, A.; Jacobson, C. A.; Farooq, U.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Biopsy type does not affect the number of stages during Mohs micrographic surgery: A retrospective study
    Journal Article

    Araneda, P.; Donoso, F.; Castro, J. C.; Uribe, P.; Rossi, A. M.; Hibler, B. P.; Droppelmann, K.; Cardenas, C.; Navarrete-Dechent, C.
    Clinical and Experimental Dermatology (2023)

    Fulltext@MSK | Save
  • Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1
    Journal Article

    Loo, K.; Kalvin, H. L.; Panageas, K. S.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
    Pigment Cell & Melanoma Research (2023)

    Fulltext@MSK | Save
  • Duration of acceptable delay until subsequent total body skin examination, given prior history of skin cancer or lesions suspicious for skin cancer: A cross-sectional survey
    Research Letter

    Yi, M. D.; Nadir, U.; Hisham, F. I.; Dave, L.; Etzkorn, J.; Albertini, J. G.; Bordeaux, J. S.; Council, M. L.; Maher, I.; Nehal, K.; more...
    Journal of the European Academy of Dermatology and Venereology (2023)

    Fulltext@MSK | Save